UniProtKB/Swiss-Prot P10253 : Variant p.Asp645Asn
Lysosomal alpha-glucosidase
Gene: GAA
Feedback ?
Variant information
Variant position:
645
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Aspartate (D) to Asparagine (N) at position 645 (D645N, p.Asp645Asn).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from medium size and acidic (D) to medium size and polar (N)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In GSD2.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
645
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
952
The length of the canonical sequence.
Location on the sequence:
ASSVPEILQFNLLGVPLVGA
D VCGFLGNTSEELCVRWTQLG
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human ASSVPEILQFNLLGVPLVGAD VCGFLGNTSEELCVRWTQLG
Mouse AYSVPDILQFNLLGVPLVGAD ICGFIGDTSEELCVRWTQLG
Rat AYSVPEILQFNLLGVPLVGAD ICGFQGNTTEELCVRWTQLG
Bovine SYSVPEILLFNLLGVPLVGAD ICGFLGNTSEELCVRWTQLG
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
70 – 952
Lysosomal alpha-glucosidase
Chain
123 – 952
76 kDa lysosomal alpha-glucosidase
Chain
204 – 952
70 kDa lysosomal alpha-glucosidase
Glycosylation
652 – 652
N-linked (GlcNAc...) asparagine
Literature citations
Glycogen storage disease type II: identification of four novel missense mutations (D645N, G648S, R672W, R672Q) and two insertions/deletions in the acid alpha-glucosidase locus of patients of differing phenotype.
Huie M.L.; Tsujino S.; Brooks S.S.; Engel A.; Elias E.; Bonthron D.T.; Bessley C.; Shanske S.; Dimauro S.; Goto Y.; Hirschhorn R.;
Biochem. Biophys. Res. Commun. 244:921-927(1998)
Cited for: VARIANTS GSD2 ASN-645; TRP-647; SER-648; GLN-672 AND TRP-672;
A case of childhood Pompe disease demonstrating phenotypic variability of p.Asp645Asn.
Kroos M.A.; Kirschner J.; Gellerich F.N.; Hermans M.M.; Van der Ploeg A.T.; Reuser A.J.; Korinthenberg R.;
Neuromuscul. Disord. 14:371-374(2004)
Cited for: VARIANT GSD2 GLN-901; VARIANT ASN-645;
Molecular and functional characterization of eight novel GAA mutations in Italian infants with Pompe disease.
Pittis M.G.; Donnarumma M.; Montalvo A.L.E.; Dominissini S.; Kroos M.; Rosano C.; Stroppiano M.; Bianco M.G.; Donati M.A.; Parenti G.; D'Amico A.; Ciana G.; Di Rocco M.; Reuser A.; Bembi B.; Filocamo M.;
Hum. Mutat. 29:E27-E36(2008)
Cited for: VARIANTS GSD2 GLY-103; CYS-191; ARG-219; TRP-224; LYS-262; ARG-293; PRO-355; LEU-375; ARG-401; ASN-489; ALA-522; PRO-552; TYR-599; TRP-638; ARG-643 AND ASN-645; CHARACTERIZATION OF VARIANTS GSD2 CYS-191; LEU-375; ARG-401; ALA-522 AND TYR-599; FUNCTION; CATALYTIC ACTIVITY;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.